JG
EPZM

Joel Greenblatt’s Epizyme, Inc EPZM Stock Holding History

Joel Greenblatt’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-8,599
Closed -$212K – 1255
2019
Q4 		$212K Buy
+8,599
New +$128K ﹤0.01% 1034
2019
Q3 		– Sell
-16,079
Closed -$202K – 1258
2019
Q2 		$202K Buy
+16,079
New +$207K ﹤0.01% 1070
2017
Q4 		– Sell
-20,310
Closed -$387K – 1092
2017
Q3 		$387K Buy
+20,310
New +$310K 0.01% 754

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Joel Greenblatt's EPZM Position: Q1 2020 in Review

Joel Greenblatt sold out of Epizyme, Inc (EPZM) in Q1 2020, closing a stake of 8,599 shares — an estimated $212K sold.

Joel Greenblatt first reported a position in EPZM in Q3 2017 and held it in 3 quarters. The position peaked at $387K in Q3 2017. 143 funds tracked by Wall St. Rank hold EPZM as of Q1 2020.

  • Joel Greenblatt reported no remaining Epizyme, Inc position as of Q1 2020 after selling out during the quarter.
  • Joel Greenblatt sold 8,599 Epizyme, Inc shares in Q1 2020, an estimated $212K.
  • Joel Greenblatt first reported a position in Epizyme, Inc in Q3 2017 and held it in 3 quarters.
  • Joel Greenblatt's Epizyme, Inc position peaked at $387K in Q3 2017.
  • 143 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2020.

Based on Gotham Asset Management's 13F filing for Q1 2020, filed 15 May 2020.